EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa

Ahmad Assi, Mohamad Farhat, Maria Catherine Rita Hachem, Ziad Zalaquett, Marven Aoun, Mohammad Daher, Amer Sebaaly, Hampig-Raphaël Kourie

Journal of Bone Oncology · 2023-12 · 43 · 100511

DOI: 10.1016/j.jbo.2023.100511 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Bone Oncology, 2023-12. Verfasst von Ahmad Assi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology Department, Hotel Dieu de France, Beirut, Lebanon. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) is an aggressive primary bone malignancy that metastasizes rapidly. The standard of care has changed little over the previous four decades, and survival rates have plateaued. In this context, tyrosine kinase inhibitors (TKIs) emerge as potential treatments. A literature search was conducted to collect data related to receptor tyrosine kinase genetic alterations and expression in OS specimens. Gene amplification and protein expression of these receptors were linked to prognosis and tumor behavior. Relevant TKIs were evaluated as monotherapies and as parts of combination therapies. Certain TKIs, such as apatinib, regorafenib, and cabozantinib, present a potential therapeutic avenue for OS patients, especially when combined with chemotherapy. Producing long-lasting responses and enhancing quality of life remain key goals in OS treatment. To this effect, optimizing the use of TKIs by identifying biomarkers predictive of response and assessing promising TKIs in larger-scale trials to validate the efficacy and safety outcomes relative to these drugs reported in phase II clinical trials. To this effect, it is necessary to identify biomarkers predictive of response to TKIs in larger-scale trials and to validate the efficacy and safety of these drugs reported in phase II clinical trials.

Schlagwörter

Stichwörter der Autor:innen

CancerManagementOsteosarcomaSarcomaTyrosine kinase inhibitors

Autor:innen und Institutionen

  • Hematology-Oncology Department, Hotel Dieu de France, Beirut, Lebanon.
  • Orthopedics Department, Hotel Dieu de France, Beirut, Lebanon.
  • Orthopedics Department, Brown University, Providence, RI, USA.

Zitieren

APA

Assi, A., Farhat, M., Hachem, M. C. R., Zalaquett, Z., Aoun, M., Daher, M., Sebaaly, A., & Kourie, H. R. (2023). Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa. Journal of Bone Oncology, 43, 100511. https://doi.org/10.1016/j.jbo.2023.100511

Vancouver

Assi A, Farhat M, Hachem MCR, Zalaquett Z, Aoun M, Daher M, et al. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa. Journal of Bone Oncology. 2023;43:100511. doi:10.1016/j.jbo.2023.100511

BibTeX
@article{Assi2023,
  author = {Assi, Ahmad and Farhat, Mohamad and Hachem, Maria Catherine Rita and Zalaquett, Ziad and Aoun, Marven and Daher, Mohammad and Sebaaly, Amer and Kourie, Hampig-Raphaël},
  title = {Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa},
  journal = {Journal of Bone Oncology},
  year = {2023},
  volume = {43},
  pages = {100511},
  doi = {10.1016/j.jbo.2023.100511}
}
Kostenlos starten →